Background. This study was designed to examine the hemodynamic, renal, and hormonal effects of brain natriuretic peptide (BNP) infusion in patients with congestive heart failure (CHF) and in control subjects.
in the regulation of fluid volume and blood pressure.2-5 ANP is secreted mainly from atria,1-6 and its plasma levels are increased in patients with congestive heart failure (CHF).6-13 We and others13-15 have shown that ANP is synthesized and secreted also from the left ventricle in patients with CHF. We and others'6-'8 have shown further that infusion of ANP improves left ventricular function by reducing both preload and afterload in patients with CHF. [16] [17] [18] Brain natriuretic peptide (BNP), first isolated from the brains of pigs'9 and subsequently from the hearts of pigs20 and rats,2122 forms a peptide family with ANP involved in the regulation of blood pressure and fluid volume. [23] [24] [25] 
Results

Hemodynamic Responses to BNP
Hemodynamic responses to BNP infusion in patients with CHF and control subjects are described in Figure 2 .
Heart rate did not change significantly during the infusion in the CHF group. On the other hand, it significantly increased at the end of the infusion (p<0.05) in the control group. Mean arterial pressure was significantly higher in the CHF group than the control group (102±+7 mm Hg versus 87±6 mm Hg,p<0.05) at baseline and did not change significantly in the CHF group, whereas it decreased from 87±6 mm Hg before the infusion to 79±6 mm Hg at the end of the infusion in the control group (p<0.05). The pulmonary capillary wedge pressure was significantly higher in the CHF group than in the control group (21±3 mm Hg versus 5+± 1 mm Hg, p<0.01) and decreased significantly during infusion in both the CHF group (from 21±3 mm Hg to 14±4 mm Hg, p<0.05) and the control group (from 5±1 mm Hg to 2+1 mm Hg, p<0.01). These reductions were sustained for 30 minutes after the end of the infusion in the CHF group (p<0.05) and in the control group (p<0.01). Right atrial pressure, which was higher in the CHF group than in the control group at baseline (7+2 mm Hg versus 3 + 1 mm Hg, p <0.01), did not change significantly during the infusion but decreased significantly after the end of the infusion in both groups (p<O.OS, respectively).
Cardiac index was significantly lower in the CHF group than in the control group at baseline (2.4±0.2 The results of all hormonal effects are summarized in Table 1 .
Plasma BNP levels were much higher in the CHF group than in the control group before BNP infusion (453±+190 pg/ml versus 34± 13 pg/ml,p<0.01). After the beginning of BNP infusion, plasma BNP levels promptly increased, reaching a peak at the end of the infusion in both the CHF group and the control group (9,129+1,194 pg/ml and 7,687+1,100 pg/ml, respectively). After the end of the infusion, plasma levels decreased gradually but were significantly higher at 30 minutes after the end of the infusion than baseline levels both in the CHF group (1,519±368 pg/ml,p<0.01) and in the control group (471± 107 pg/ml, p<0.01). Plasma levels of ANP in the CHF group were also higher than those in the control group (262±+65 versus 65± 11 pg/ml,p<0.01) before BNP infusion. Plasma ANP levels significantly increased in the CHF group (from 262±t65 pg/ml to 316+50 pg/ml, p<0.05) and in the control group (from 65±+11 pg/ml to 87±f15 pg/ml, p<0.05). The plasma cGMP levels before BNP infusion were significantly higher in the CHF group than in the control group (25.1+±3.3 pmol/ml versus 7.7±1.1 pmol/ml, p<0.01). cGMP levels increased in both groups (p<0.01, respectively) during infusion and remained elevated over 30 minutes after the end of the infusion in both groups (p<0.01, respectively). The difference of plasma cGMP levels between the two groups disappeared during and after the infusion. Plasma renin activity was higher in the CHF group than in the control group (2.9±+0.9 ng/ml/hr versus 0.8+0.2 ng/ml/hr,p<0.05) before infusion and did not change significantly during infusion in both groups.
Plasma aldosterone levels tended to be higher in the CHF group than in the control group (91.1 ± 34.3 pg/ml versus 43.3 ± 12.1 pg/ml) and were significantly suppressed by BNP infusion.
Plasma norepinephrine levels were significantly higher in the CHF group than in the control group at baseline (725±170 pg/ml versus 216±25 pg/ml, p<0.01) and increased significantly to 400±28 pg/ml (p<0.01) at the end of the infusion in the control group. There were no significant changes in plasma epinephrine levels in response to BNP infusion in both groups.
Renal Responses to BNP
Renal responses to BNP infusion are summarized in Figure 3 .
Urine volume increased significantly during BNP infusion in both groups (from 2.3+±0.7 ml/min to 7.5+1.9 ml/min, p<0.01 for the control group and from 0.8±0.2 ml/min to 5.3± 1.0 ml/min, p<0.01 for the CHF group) and after the end of the infusion in the CHF group (from 0.8±0.2 ml/min to 4.3±0.8 ml/min, p<0.01).
Urinary excretion of sodium increased significantly significantly greater in the CHF group than in the control group during and after the end of the infusion (p<0.01, respectively). Urinary potassium excretion increased significantly both during and after the end of the infusion in the CHF group (p<0.01, respectively) and during infusion in the control group (p<O.O5).
Creatinine clearance increased during infusion in both groups, but the increase was significant only in the control group (p <0.05).
Effects of BNP on Blood Cell Counts and Blood
Biochemistry
BNP infusion showed no significant effects on the values of blood cell counts or of blood biochemistry including serum sodium, potassium, and chloride concentrations, osmotic pressure, and serum transaminases.
Discussion BNP, first isolated from the brains of pigs'9 and subsequently from the hearts of pigs,20 rats,21"22 and humans,26 forms a peptide family with ANP involved in the regulation of blood pressure and blood volume. [23] [24] [25] We have isolated human BNP and determined its 32-amino-acid sequence,26 which has structural diversity among species. It has been subsequently cleared that the biological actions of BNPs are species specific, unlike those of ANP.33 We have also shown that BNP is secreted predominantly from the ventricle29 and that its plasma levels are markedly increased in patients with CHF (in relation to its severity) and surpass plasma levels of ANP. [27] [28] [29] Previous studies have shown that the infusion of ANP decreases pulmonary capillary wedge pressure and systemic vascular resistance and increases cardiac output, thereby improving left ventricular function by reducing both preload and afterload in patients with CHF.16-18 Diuretic and natriuretic responses to ANP infusion, however, were blunted in these patients. [16] [17] [18] The present study has shown that plasma levels of BNP are increased in patients with CHF compared with control subjects at baseline; this is in agreement with the results of our previous studies.27 -29 The baseline levels in control subjects were slightly higher than in our previous reports.27-29 This is probably because one patient with mild hypertension and two patients with history of mild hypertension were included in the control group in this study. During the infusion of BNP, plasma BNP levels increased markedly to approximately 150-fold of baseline levels in control subjects and 20-fold in patients with CHF; levels remained elevated even at 30 minutes after the end of the infusion. This is in agreement with the results of our previous report, which demonstrated that the clearance of BNP in the circulation is slower than that of ANPJ29
The infusion of BNP decreased pulmonary capillary wedge pressure, right atrial pressure, and systemic vascular resistance, and increased stroke volume index in patients with CHF, indicating that infusion of BNP improves left ventricular function in patients with CHF. In control subjects, however, BNP infusion did not increase stroke volume index, although it decreased pulmonary capillary wedge pressure and systemic vascular resistance. Thus, BNP has a beneficial effect on left ventricular function in patients with CHF (hemodynamic effects of BNP are similar to those of ANP).
The infusion of BNP markedly increased urine volume and urinary excretion of sodium, potassium, and chloride in patients with CHF and in control subjects. The degree of urinary excretion of sodium and of chloride during BNP infusion was, however, significantly higher in patients with CHF than in control subjects. This is in sharp contrast with the case of ANP infusion, to which the patients with CHF showed blunted natriuretic response. 16 During infusion of BNP, plasma levels of cGMP increased markedly both in patients with CHF and in control subjects and became similar between the two groups.
Infusion of BNP did not change plasma renin activity in patients with CHF or in control subjects. Because diuretics and vasodilators stimulate the renin-angiotensin system, no change in plasma renin activity (despite the decrease in blood pressure and increased sodium excretion shown in this study) suggests that BNP exerts an inhibitory effect on the juxtaglomerular apparatus. Despite the absence of changes in plasma renin activity, BNP infusion decreased plasma aldosterone levels significantly. Therefore, the inhibition of plasma aldosterone by BNP was probably due to a direct effect on the adrenal gland, as is the case for ANP.16 It is likely that inhibition of aldosterone secretion may contribute to natriuresis with the longer period of BNP infusion.
Plasma norepinephrine levels increased significantly in control subjects and tended to increase in patients with CHF in response to BNP infusion. This is probably due to baroreceptor-mediated sympathetic discharge in response to peripheral vasodilation and a decrease in arterial blood pressure. It is interesting to note that ANP infusion decreased or tended to decrease plasma levels of norepinephrine in patients with CHF,16'8 probably because ANP has a sympatholytic effect47 and baroreceptor activity is blunted in these patients.48,49 BNP thus seems to have less effect than ANP on the sympathetic nervous system.
We have previously reported that plasma levels of BNP as well as ANP are increased as the severity of CHF increases27-29 and suggested discrete physiological and pathophysiological roles of BNP in the dual natriuretic peptide system. The present study shows that BNP infusion decreases both preload and afterload and increases cardiac output in patients with CHF. Moreover, in contrast with ANP, the natriuretic response to BNP was not blunted in patients with CHF. These results indicate that increased secretion of BNP plays an important role in the compensation of CHF in association with ANP. Because BNP has an enhanced natriuretic effect and a longer duration of action in patients with CHF, this study raises the possibility that BNP is more advantageous than ANP as a therapeutic agent for CHF. The dose of BNP infused in this study was large, however, and plasma levels were increased up to one order of magnitude higher than the pathologically increased endogenous levels. Thus, the effects of BNP infusion in this study may be pharmacological rather than physiological. Further studies using lower doses will be required to assess the physiological and pathophysiological significance of BNP.
